Outcomes after delayed primary percutaneous coronary intervention vs. pharmaco-invasive strategy in ST-segment

Jarle Jortveit1, Are Hugo Pripp2, Sigrun Halvorsen3

  • 1Department of Cardiology, Sørlandet Hospital, Arendal, Box 783, Stoa, 4809 Arendal, Norway.

Insights

For ST-segment elevation myocardial infarction (STEMI) patients not receiving timely primary percutaneous coronary intervention (pPCI), a pharmaco-invasive (P-I) strategy shows better long-term survival than delayed or late pPCI. However, P-I strategies may increase bleeding complications.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Acute Coronary Syndromes

Background:

  • Primary percutaneous coronary intervention (pPCI) is the gold standard for ST-segment elevation myocardial infarction (STEMI) if performed within 120 minutes.
  • Optimal reperfusion strategy for STEMI patients unable to receive timely pPCI remains unclear.
  • Pharmaco-invasive (P-I) strategy offers an alternative when timely pPCI is not feasible.

Purpose of the Study:

  • To compare long-term outcomes of delayed/late pPCI versus a P-I strategy in STEMI patients.
  • To evaluate the impact of reperfusion strategies on mortality and bleeding complications.
  • To inform clinical decision-making for STEMI management when timely pPCI is unavailable.

Main Methods:

  • Retrospective analysis of STEMI patients from the Norwegian Myocardial Infarction Registry (NORMI) (2013-2019).
  • Inclusion criteria: STEMI diagnosis, symptom onset to first medical contact ≤12 hours, available timelines.
  • Comparison groups: timely pPCI, delayed pPCI (121-180 min), late pPCI (>180 min), and P-I strategy.

Main Results:

  • A total of 13,221 STEMI patients met inclusion criteria.
  • Mortality was higher in delayed pPCI (aHR 1.3) and late pPCI (aHR 1.4) compared to the P-I strategy.
  • Bleeding complications were more frequent in the P-I strategy group.

Conclusions:

  • In STEMI patients not receiving timely pPCI, a P-I strategy is associated with improved long-term survival.
  • Delayed or late pPCI in this patient group is linked to increased mortality.
  • While P-I strategies may increase bleeding risk, they offer a survival benefit over delayed interventions.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
70
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
208
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
114
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
95
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
85
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
62